Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment

Meiling Song; Wenjing Pan; Xinjie Yu; Jie Ren; Congli Tang; Zhu Chen; Zhe Wang; Yan Deng; Nongyue He; Hongna Liu; Song Li

doi:10.1002/mco2.70193

MedComm ›› 2025, Vol. 6 ›› Issue (6) :e70193 DOI: 10.1002/mco2.70193

REVIEW

Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment

Meiling Song ¹
, Wenjing Pan ²^,³^,⁴
, Xinjie Yu ¹
, Jie Ren ²^,³^,⁴
, Congli Tang ⁵
, Zhu Chen ²^,³^,⁶
, Zhe Wang ⁷
, Yan Deng ²^,³^,⁶
, Nongyue He ¹^,⁵
, Hongna Liu ²^,³^,⁴
, Song Li ¹^,²^,³^,⁴^,⁶

Author information +

History +

PDF

Abstract

Minimal residual disease (MRD) serves as a pivotal biomarker for the clinical diagnosis and subsequent treatment of cancer patients. In hematological malignancies, MRD pose an increasingly serious threat to the health of Chinese people. Accurate MRD detection is essential for assessing relapse risk and optimizing therapeutic strategies, yet current methods such as flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS) each have distinct limitations, and significant gaps remain in achieving optimal sensitivity and specificity of these technologies. This review provides a comprehensive analysis of MRD detection methods, high-lighting their clinical implications, including their roles in treatment decision-making, risk stratification, and patient outcomes. It discusses the strengths and weaknesses of existing techniques and explores emerging technologies that promise enhanced diagnostic precision. Key advancements such as integrating NGS with other methodologies and novel approaches like liquid biopsy and PCR are examined. The review underscores the academic and practical value of early and accurate MRD detection, emphasizing its impact on improving patient management and treatment outcomes. By addressing the limitations of current technologies and exploring future directions, this review aims to advance the field and support personalized medicine approaches to cancer treatment.

Keywords

MRD / detection methods / next-generation sequencing / clinical implication

Cite this article

Download citation ▾

Meiling Song, Wenjing Pan, Xinjie Yu, Jie Ren, Congli Tang, Zhu Chen, Zhe Wang, Yan Deng, Nongyue He, Hongna Liu, Song Li. Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment. MedComm, 2025, 6(6): e70193 DOI:10.1002/mco2.70193

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	W. Liu, J. Liu, Y. Song, et al., “Mortality of Lymphoma and Myeloma in China, 2004-2017: An Observational Study,” Journal of Hematology & Oncology 12, no. 1 (2019): 22.

[2]	Chinese Society of Immunology, Clinical Flow Cytometry Group. Expert Consensus on Minimal Residual Disease Detection of Acute Leukemia and Plasma Cell Neoplasms by Multi-parameter Flow Cytometry. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi 2017; 38(12): 1001-1011.

[3]	M. Bernardi, F. Ferrara, M. G. Carrabba, et al., “MRD in Venetoclax-Based Treatment for AML: Does It Really Matter?,” Frontiers in Oncology 12 (2022): 890871.

[4]	F. Yang, T. Anekpuritanang, and R. D. Press, “Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia,” Molecular Diagnosis & Therapy 24, no. 1 (2020): 1-13.

[5]	W. Li. Measurable Residual Disease Testing in Acute Leukemia: Technology and Clinical Significance. In: Li W, ed. “Leukemia” (Brisbane (AU): Exon Publications, 2022). October 16,.

[6]	A. Perrot, V. Lauwers-Cances, J. Corre, et al., “Minimal Residual Disease Negativity Using Deep Sequencing Is a Major Prognostic Factor in Multiple Myeloma,” Blood 132, no. 23 (2018): 2456-2464.

[7]	G. J. Schuurhuis, M. Heuser, S. Freeman, et al., “Minimal/Measurable Residual Disease in AML: A Consensus Document From the European Leukemia Net MRD Working Party,” Blood 131, no. 12 (2018): 1275-1291.

[8]	M. J. L. Aitken, F. Ravandi, K. P. Patel, and N. J. Short, “Prognostic and Therapeutic Implications of Measurable Residual Disease in Acute Myeloid Leukemia,” Journal of Hematology & Oncology 14, no. 1 (2021): 137.

[9]	R. B. Walter, Y. Ofran, A. Wierzbowska, et al., “Measurable Residual Disease as a Biomarker in Acute Myeloid Leukemia: Theoretical and Practical Considerations,” Leukemia 35, no. 6 (2021): 1529-1538.

[10]	A. Venditti, A. Piciocchi, A. Candoni, et al., “GIMEMA AML1310 Trial of Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia,” Blood 134, no. 12 (2019): 935-945.

[11]	L. L. Ngai, A. Kelder, J. Janssen, G. J. Ossenkoppele, and J. Cloos, “MRD Tailored Therapy in AML: What We Have Learned So Far,” Frontiers in Oncology 10 (2021): 603636.

[12]	S. A. Buckley, F. R. Appelbaum, and R. B. Walter, “Prognostic and Therapeutic Implications of Minimal Residual Disease at the Time of Transplantation in Acute Leukemia,” Bone Marrow Transplantation 48, no. 5 (2013): 630-641.

[13]	R. P. Correia, R. D. Puga, N. H. Muto, et al., “High-throughput Sequencing of Immunoglobulin Heavy Chain for Minimal Residual Disease Detection in B-lymphoblastic Leukemia,” International Journal of Laboratory Hematology 43, no. 4 (2021): 724-731.

[14]	D. A. Berry, S. Zhou, H. Higley, et al., “Association of Minimal Residual Disease with Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis,” JAMA Oncology 3, no. 7 (2017): e170580.

[15]	H. Rieder, W. D. Ludwig, W. Gassmann, et al., “Prognostic Significance of Additional Chromosome Abnormalities in Adult Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukaemia,” British Journal of Haematology 95, no. 4 (1996): 678-691.

[16]	A. M. Parrott, V. V. Murty, C. Walsh, A. Christiano, G. Bhagat, and B. Alobeid, “Interphase Fluorescence in Situ Hybridization Analysis of CD19-selected Cells: Utility in Detecting Disease in Post-therapy Samples of B-cell Neoplasms,” Cancer Medicine 10, no. 8 (2021): 2680-2689.

[17]	E. Klyuchnikov, A. Badbaran, R. Massoud, et al., “Post-Transplantation Multicolored Flow Cytometry-Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients with Refractory Acute Myeloid Leukemia,” Transplantation and Cellular Therapy 28, no. 5 (2022): 267. e1-e7.

[18]

J. R. B. Martins, L. N. Moraes, S. S. Cury, et al., “MiR-125a-3p and MiR-320b Differentially Expressed in Patients With Chronic Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate,” International Journal of Molecular Sciences 22, no. 19 (2021): 10216.

[19]	K. L. Juul-Dam, H. B. Ommen, C. G. Nyvold, et al., “Measurable Residual Disease Assessment by qPCR in Peripheral Blood Is an Informative Tool for Disease Surveillance in Childhood Acute Myeloid Leukaemia,” British Journal of Haematology 190, no. 2 (2020): 198-208.

[20]	M. Heuser, B. Heida, K. Büttner, et al., “Posttransplantation MRD Monitoring in Patients With AML by next-generation Sequencing Using DTA and Non-DTA Mutations,” Blood Advances 5, no. 9 (2021): 2294-2304.

[21]	N. Patkar, R. Kodgule, C. Kakirde, et al., “Clinical Impact of Measurable Residual Disease Monitoring by ultradeep next Generation Sequencing in NPM1 Mutated Acute Myeloid Leukemia,” Oncotarget 9, no. 93 (2018): 36613-36624.

[22]	M. Svaton, A. Skotnicova, L. Reznickova, et al., “NGS Better Discriminates True MRD Positivity for the Risk Stratification of Childhood ALL Treated on an MRD-based Protocol,” Blood 141, no. 5 (2023): 529-533.

[23]	H. Mai, Q. Li, G. Wang, et al., “Clinical Application of next-generation Sequencing-based Monitoring of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia,” Journal of Cancer Research and Clinical Oncology 149, no. 7 (2023): 3259-3266.

[24]	C. Saygin, J. Cannova, W. Stock, and L. Muffly, “Measurable Residual Disease in Acute Lymphoblastic Leukemia: Methods and Clinical Context in Adult Patients,” Haematologica 107, no. 12 (2022): 2783-2793.

[25]	J. Moritz, A. Schwab, A. Reinisch, A. Zebisch, H. Sill, and A. Wölfler, “Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions,” Biomedicines 12, no. 3 (2024): 599.

[26]	Y. Liu, Y. Zhang, W. Hao, D. Liu, A. Li, and C. Chen, “Localized Residual Leukaemia in Bone Marrow of Extremities,” Nuclear Medicine Communications 29, no. 6 (2008): 542-545.

[27]	Z. He, Z. Chen, M. Tan, et al., “A Review on Methods for Diagnosis of Breast Cancer Cells and Tissues,” Cell Proliferation 53, no. 7 (2020): e12822.

[28]	M. Sawińska and D. Ładoń, “Mechanism, Detection and Clinical Significance of the Reciprocal Translocation T(12;21)(p12;q22) in the Children Suffering From Acute Lymphoblastic Leukaemia,” Leukemia Research 28, no. 1 (2004): 35-42.

[29]	X. Qin, M. Y. Zhang, and W. J. Liu, “Application of Minimal Residual Disease Monitoring in Pediatric Patients With Acute Lymphoblastic Leukemia,” European Review for Medical and Pharmacological Sciences 22, no. 20 (2018): 6885-6895.

[30]	Y. Zhou and B. L. Wood, “Methods of Detection of Measurable Residual Disease in AML,” Current Hematologic Malignancy Reports 12, no. 6 (2017): 557-567.

[31]	W. Li. Flow Cytometry in the Diagnosis of Leukemias. In: Li W, ed. “Leukemia” (Brisbane (AU): Exon Publications, 2022). October 16,.

[32]	W. Li, R. Morgan, R. Nieder, S. Truong, S. S. M. Habeebu, and A. A. Ahmed, “Normal or Reactive minor Cell Populations in Bone Marrow and Peripheral Blood Mimic Minimal Residual Leukemia by Flow Cytometry,” Cytometry Part B, Clinical cytometry 100, no. 5 (2021): 590-601.

[33]

J. M. C. Rocha, S. G. Xavier, M. E. L. Souza, M. Murao, and B. M. de Oliveira, “Comparison Between Flow Cytometry and Standard PCR in the Evaluation of MRD in Children With Acute Lymphoblastic Leukemia Treated With the GBTLI LLA - 2009 Protocol,” Pediatric Hematology and Oncology 36, no. 5 (2019): 287-301.

[34]	H. Y. Kim, I. Y. Yoo, D. J. Lim, et al., “Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients With Multiple Myeloma,” Annals of Laboratory Medicine 42, no. 5 (2022): 558-565.

[35]	S. Hrabovsky, F. Folber, J. M. Horacek, et al., “Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia,” Clinical Lymphoma, Myeloma & Leukemia 18, no. 11 (2018): 743-748.

[36]	M. J. Borowitz, B. L. Wood, M. Devidas, et al., “Prognostic Significance of Minimal Residual Disease in High Risk B-ALL: A Report From Children's Oncology Group Study AALL0232,” Blood 126, no. 8 (2015): 964-971.

[37]	B. L. Wood, “Principles of Minimal Residual Disease Detection for Hematopoietic Neoplasms by Flow Cytometry,” Cytometry Part B, Clinical Cytometry 90, no. 1 (2016): 47-53.

[38]	C. Charalampous and T. Kourelis, “Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease with Maximal Implications,” Frontiers in Oncology 11 (2022): 801851.

[39]	J. Flores-Montero, L. Sanoja-Flores, B. Paiva, et al., “Next Generation Flow for Highly Sensitive and Standardized Detection of Minimal Residual Disease in Multiple Myeloma,” Leukemia 31, no. 10 (2017): 2094-2103.

[40]	K. C. Anderson, D. Auclair, S. J. Adam, et al., “Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration,” Clinical Cancer Research 27, no. 19 (2021): 5195-5212.

[41]	H. Dong, C. Tang, Z. He, et al., “Rapid Identification of Diarrheagenic Escherichia coli Based on Barcoded Magnetic Bead Hybridization,” Chinese Chemical Letters 31 (2020): 1812-1816.

[42]	Z. He, C. Tang, X. Chen, et al., “Based on Magnetic Beads to Develop the Kit for Extraction of High-quality Cell-free DNA From Blood of Breast Cancer Patients,” Materials Express 9 (2019): 956-961.

[43]	C. Tang, Z. He, H. Liu, et al., “Application of Magnetic Nanoparticles in Nucleic Acid Detection,” Journal of Nanobiotechnology 18, no. 1 (2020): 62.

[44]	X. Wang, Y. Liu, H. Liu, et al., “Recent Advances and Application of Whole Genome Amplification in Molecular Diagnosis and Medicine,” MedComm 3, no. 1 (2022): e116.

[45]	V. H. van der Velden, G. Cazzaniga, A. Schrauder, et al., “Analysis of Minimal Residual Disease by Ig/TCR Gene Rearrangements: Guidelines for Interpretation of Real-time Quantitative PCR Data,” Leukemia 21, no. 4 (2007): 604-611.

[46]	M. Peham, S. Panzer, K. Fasching, et al., “Low Frequency of Clonotypic Ig and T-cell Receptor Gene Rearrangements in T(4;11) Infant Acute Lymphoblastic Leukaemia and Its Implication for the Detection of Minimal Residual Disease,” British Journal of Haematology 117, no. 2 (2002): 315-321.

[47]	T. Szczepański, “Why and How to Quantify Minimal Residual Disease in Acute Lymphoblastic Leukemia?,” Leukemia 21, no. 4 (2007): 622-626.

[48]

J. Gabert, E. Beillard, V. H. van der Velden, et al., “Standardization and Quality Control Studies of ‘Real-time’ quantitative Reverse Transcriptase Polymerase Chain Reaction of Fusion Gene Transcripts for Residual Disease Detection in Leukemia—a Europe Against Cancer Program,” Leukemia 17, no. 12 (2003): 2318-2357.

[49]	V. H. van der Velden, N. Boeckx, M. Gonzalez, et al., “Differential Stability of Control Gene and Fusion Gene Transcripts Over Time May Hamper Accurate Quantification of Minimal Residual Disease-a Study Within the Europe Against Cancer Program,” Leukemia 18, no. 4 (2004): 884-886.

[50]	J. J. Salk, M. W. Schmitt, and L. A. Loeb, “Enhancing the Accuracy of next-generation Sequencing for Detecting Rare and Subclonal Mutations,” Nature Reviews Genetics 19, no. 5 (2018): 269-285.

[51]	A. Kruse, N. Abdel-Azim, H. N. Kim, et al., “Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia,” International Journal of Molecular Sciences 21, no. 3 (2020): 1054.

[52]	M. A. Pulsipher, C. Carlson, B. Langholz, et al., “IgH-V(D)J NGS-MRD Measurement Pre- and Early Post-allotransplant Defines Very Low- and Very High-risk all Patients,” Blood 125, no. 22 (2015): 3501-3508.

[53]	M. A. Pulsipher, X. Han, S. L. Maude, et al., “Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse After Tisagenlecleucel in Children and Young Adults With Acute Lymphoblastic Leukemia,” Blood Cancer Discovery 3, no. 1 (2022): 66-81.

[54]	P. Langerhorst, S. Noori, M. Zajec, et al., “Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow,” Clinical Chemistry 67, no. 12 (2021): 1689-1698.

[55]	Y. Li, J. Solis-Ruiz, F. Yang, et al., “NGS-defined Measurable Residual Disease (MRD) After Initial Chemotherapy as a Prognostic Biomarker for Acute Myeloid Leukemia,” Blood Cancer Journal 13, no. 1 (2023): 59.

[56]	C. H. Tsai, J. L. Tang, F. M. Tien, et al., “Clinical Implications of Sequential MRD Monitoring by NGS at 2 Time Points After Chemotherapy in Patients With AML,” Blood Advances 5, no. 10 (2021): 2456-2466.

[57]	J. M. Yoest, C. L. Shirai, and E. J. Duncavage, “Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia,” Frontiers in Cell and Developmental Biology 8 (2020): 249.

[58]	X. Niu, S. Li, P. Li, et al., “Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients,” Frontiers in Immunology 11 (2020): 582010.

[59]	M. Kotrova, K. Muzikova, E. Mejstrikova, et al., “The Predictive Strength of next-generation Sequencing MRD Detection for Relapse Compared With Current Methods in Childhood ALL,” Blood 126, no. 8 (2015): 1045-1047.

[60]	Y. Wang and F. Q. Wen, “Latest Advances in Minimal Residual Disease Evaluation in B-cell Lymphoproliferative Disease,” Zhongguo Dang Dai Er Ke Za Zhi 22, no. 6 (2020): 667-671.

[61]	G. Wright, E. Watt, S. Inglott, T. Brooks, J. Bartram, and S. P. Adams, “Clinical Benefit of a High-throughput Sequencing Approach for Minimal Residual Disease in Acute Lymphoblastic Leukemia,” Pediatric Blood & Cancer 66, no. 8 (2019): e27787.

[62]	Y. Huang, H. Zhao, M. Shao, et al., “Predictive Value of next-generation Sequencing-based Minimal Residual Disease After CAR-T Cell Therapy,” Bone Marrow Transplantation 57, no. 8 (2022): 1350-1353.

[63]	A. Schumich, M. Maurer-Granofszky, A. Attarbaschi, et al., “Flow-cytometric Minimal Residual Disease Monitoring in Blood Predicts Relapse Risk in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia in Trial AIEOP-BFM-ALL 2000,” Pediatric Blood & Cancer 66, no. 5 (2019): e27590.

[64]	V. H. van der Velden, D. C. Jacobs, A. J. Wijkhuijs, et al., “Minimal Residual Disease Levels in Bone Marrow and Peripheral Blood Are Comparable in Children With T Cell Acute Lymphoblastic Leukemia (ALL), but Not in Precursor-B-ALL,” Leukemia 16, no. 8 (2002): 1432-1436.

[65]	A. Setiadi, D. Owen, A. Tsang, R. Milner, and S. Vercauteren, “The Significance of Peripheral Blood Minimal Residual Disease to Predict Early Disease Response in Patients With B-cell Acute Lymphoblastic Leukemia,” International Journal of Laboratory Hematology 38, no. 5 (2016): 527-534.

[66]	E. Coustan-Smith, J. Sancho, M. L. Hancock, et al., “Use of Peripheral Blood Instead of Bone Marrow to Monitor Residual Disease in Children With Acute Lymphoblastic Leukemia,” Blood 100, no. 7 (2002): 2399-2402.

[67]	J. Bartram, G. Wright, S. Adams, et al., “High-throughput Sequencing of Peripheral Blood for Minimal Residual Disease Monitoring in Childhood Precursor B-cell Acute Lymphoblastic Leukemia: A Prospective Feasibility Study,” Pediatric Blood & Cancer 69, no. 3 (2022): e29513.

[68]	V. H. van der Velden and J. J. van Dongen, “MRD Detection in Acute Lymphoblastic Leukemia Patients Using Ig/TCR Gene Rearrangements as Targets for Real-time Quantitative PCR,” Methods in Molecular Biology 538 (2009): 115-150.

[69]	M. Ladetto, M. Brüggemann, L. Monitillo, et al., “Next-generation Sequencing and Real-time Quantitative PCR for Minimal Residual Disease Detection in B-cell Disorders,” Leukemia 28, no. 6 (2014): 1299-1307.

[70]	Y. Sekiya, Y. Xu, H. Muramatsu, et al., “Clinical Utility of next-generation Sequencing-based Minimal Residual Disease in Paediatric B-cell Acute Lymphoblastic Leukaemia,” British Journal of Haematology 176, no. 2 (2017): 248-257.

[71]	D. Wu, R. O. Emerson, A. Sherwood, et al., “Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-throughput Sequencing of IGH,” Clinical Cancer Research 20, no. 17 (2014): 4540-4548.

[72]	F. Thol, B. Kölking, F. Damm, et al., “Next-generation Sequencing for Minimal Residual Disease Monitoring in Acute Myeloid Leukemia Patients With FLT3-ITD or NPM1 Mutations,” Genes, Chromosomes & Cancer 51, no. 7 (2012): 689-695.

[73]	J. J. van Dongen, V. H. van der Velden, M. Brüggemann, and A. Orfao, “Minimal Residual Disease Diagnostics in Acute Lymphoblastic Leukemia: Need for Sensitive, Fast, and Standardized Technologies,” Blood 125, no. 26 (2015): 3996-4009.

[74]	A. C. Logan, “Measurable Residual Disease in Acute Lymphoblastic Leukemia: How Low Is Low Enough?,” Best Practice & Research, Clinical Haematology 35, no. 4 (2022): 101407.

[75]	L. Muffly, V. Sundaram, C. Chen, et al., “Concordance of Peripheral Blood and Bone Marrow Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia,” Blood Advances 5, no. 16 (2021): 3147-3151.

[76]	S. Stasik, C. Burkhard-Meier, M. Kramer, et al., “Deep Sequencing in CD34+ Cells From Peripheral Blood Enables Sensitive Detection of Measurable Residual Disease in AML,” Blood Advances 6, no. 11 (2022): 3294-3303.

[77]	D. Wu, A. Sherwood, J. R. Fromm, et al., “High-throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia,” Science Translational Medicine 4, no. 134 (2012): 134ra63.

[78]	M. Kircher, S. Sawyer, and M. Meyer, “Double Indexing Overcomes Inaccuracies in Multiplex Sequencing on the Illumina Platform,” Nucleic Acids Res. 40, no. 1 (2012): e3.

[79]	M. Kircher, “Analysis of High-throughput Ancient DNA Sequencing Data,” Methods in Molecular Biology 840 (2012): 197-228.

[80]	M. C. Nelson, H. G. Morrison, J. Benjamino, S. L. Grim, and J. Graf, “Analysis, Optimization and Verification of Illumina-generated 16S rRNA Gene Amplicon Surveys,” PLoS ONE 9, no. 4 (2014): e94249.

[81]	M. A. Quail, M. Smith, D. Jackson, et al., “SASI-Seq: Sample Assurance Spike-Ins, and Highly Differentiating 384 Barcoding for Illumina Sequencing,” BMC Genomics [Electronic Resource] 15, no. 1 (2014): 110.

[82]	E. S. Wright and K. H. Vetsigian, “Quality Filtering of Illumina Index Reads Mitigates Sample Cross-talk,” BMC Genomics [Electronic Resource] 17, no. 1 (2016): 876.

[83]	J. Bartram, E. Mountjoy, T. Brooks, et al., “Accurate Sample Assignment in a Multiplexed, Ultrasensitive, High-Throughput Sequencing Assay for Minimal Residual Disease,” The Journal of Molecular Diagnostics 18, no. 4 (2016): 494-506.

[84]	C. S. Carlson, R. O. Emerson, A. M. Sherwood, et al., “Using Synthetic Templates to Design an Unbiased Multiplex PCR Assay,” Nature Communications 4 (2013): 2680.

[85]	S. A. Grupp, M. Kalos, D. Barrett, et al., “Chimeric Antigen Receptor-modified T Cells for Acute Lymphoid Leukemia [Published Correction Appears in N Engl J Med. 2016 Mar 10;374(10):998,” New England Journal of Medicine 368, no. 16 (2013): 1509-1518, https://doi.org/10.1056/NEJMx160005.

[86]	M. Heuser, S. D. Freeman, G. J. Ossenkoppele, et al., “2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document From the European LeukemiaNet MRD Working Party,” Blood 138, no. 26 (2021): 2753-2767.

[87]	J. Cloos, L. L. Ngai, and M. Heuser, “Understanding Differential Technologies for Detection of MRD and How to Incorporate Into Clinical Practice,” Hematology American Society of Hematology Education Program 2023, no. 1 (2023): 682-690.

[88]

R. B. Walter, T. A. Gooley, B. L. Wood, et al., “Impact of Pretransplantation Minimal Residual Disease, as Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia,” Journal of Clinical Oncology 29, no. 9 (2011): 1190-1197.

[89]	R. B. Walter, S. A. Buckley, J. M. Pagel, et al., “Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for AML in First and Second Complete Remission,” Blood 122, no. 10 (2013): 1813-1821.

[90]	Y. Zhou, M. Othus, D. Araki, et al., “Pre- and Post-transplant Quantification of Measurable (‘minimal’) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia,” Leukemia 30, no. 7 (2016): 1456-1464.

[91]	D. Araki, B. L. Wood, M. Othus, et al., “Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move toward a Minimal Residual Disease-Based Definition of Complete Remission?,” Journal of Clinical Oncology 34, no. 4 (2016): 329-336.

[92]	J. Versluis and J. J. Cornelissen, “Risks and Benefits in a Personalized Application of Allogeneic Transplantation in Patients With AML in First CR,” Seminars in Hematology 56, no. 2 (2019): 164-170.

[93]	X. Chen, H. Xie, B. L. Wood, et al., “Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia,” Journal of Clinical Oncology 33, no. 11 (2015): 1258-1264.

[94]	S. D. Freeman, R. K. Hills, P. Virgo, et al., “Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk without NPM1 Mutations,” Journal of Clinical Oncology 36, no. 15 (2018): 1486-1497.

[95]	B. Falini, L. Brunetti, P. Sportoletti, and M. P. Martelli, “NPM1-mutated Acute Myeloid Leukemia: From Bench to Bedside,” Blood 136, no. 15 (2020): 1707-1721.

[96]	J. Zarka, N. J. Short, R. Kanagal-Shamanna, and G. C. Issa, “Nucleophosmin 1 Mutations in Acute Myeloid Leukemia,” Genes (Basel) 11, no. 6 (2020): 649.

[97]	P. Jain, H. Kantarjian, K. Patel, et al., “Mutated NPM1 in Patients With Acute Myeloid Leukemia in Remission and Relapse,” Leukemia & Lymphoma 55, no. 6 (2014): 1337-1344.

[98]	A. Ivey, R. K. Hills, M. A. Simpson, et al., “Assessment of Minimal Residual Disease in Standard-Risk AML,” New England Journal of Medicine 374, no. 5 (2016): 422-433.

[99]	J. Krönke, R. F. Schlenk, K. O. Jensen, et al., “Monitoring of Minimal Residual Disease in NPM1-mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group,” Journal of Clinical Oncology 29, no. 19 (2011): 2709-2716.

[100]

M. Balsat, A. Renneville, X. Thomas, et al., “Postinduction Minimal Residual Disease Predicts Outcome and Benefit from Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with NPM1 Mutation: A Study by the Acute Leukemia French Association Group,” Journal of Clinical Oncology 35, no. 2 (2017): 185-193.

[101]

F. Lussana, C. Caprioli, P. Stefanoni, et al., “Molecular Detection of Minimal Residual Disease Before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients With NPM1 Positive Acute Myeloid Leukemia,” Cancers (Basel) 11, no. 10 (2019): 1455.

[102]

M. Jongen-Lavrencic, T. Grob, D. Hanekamp, et al., “Molecular Minimal Residual Disease in Acute Myeloid Leukemia,” New England Journal of Medicine 378, no. 13 (2018): 1189-1199.

[103]

K. Morita, H. M. Kantarjian, F. Wang, et al., “Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia,” Journal of Clinical Oncology 36, no. 18 (2018): 1788-1797.

[104]

F. Thol, R. Gabdoulline, A. Liebich, et al., “Measurable Residual Disease Monitoring by NGS Before Allogeneic Hematopoietic Cell Transplantation in AML,” Blood 132, no. 16 (2018): 1703-1713.

[105]

J. M. Klco, C. A. Miller, M. Griffith, et al., “Association between Mutation Clearance after Induction Therapy and Outcomes in Acute Myeloid Leukemia,” Jama 314, no. 8 (2015): 811-822.

[106]

B. M. Getta, S. M. Devlin, R. L. Levine, et al., “Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia After Allogeneic Transplantation,” Biology of Blood and Marrow Transplantation 23, no. 7 (2017): 1064-1071.

[107]

A. Teixeira, L. Carreira, S. Abalde-Cela, et al., “Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review,” Cancers (Basel) 15, no. 5 (2023): 1362.

[108]

B. Paiva, J. J. van Dongen, and A. Orfao, “New Criteria for Response Assessment: Role of Minimal Residual Disease in Multiple Myeloma,” Blood 125, no. 20 (2015): 3059-3068.

[109]

B. Paiva, M. B. Vidriales, J. Cerveró, et al., “Multiparameter Flow Cytometric Remission Is the Most Relevant Prognostic Factor for Multiple Myeloma Patients Who Undergo Autologous Stem Cell Transplantation,” Blood 112, no. 10 (2008): 4017-4023.

[110]

A. C. Rawstron, J. A. Child, R. M. de Tute, et al., “Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study [published correction appears in J Clin Oncol. 2013 Dec 1;31(34):4383],” Journal of Clinical Oncology 31, no. 20 (2013): 2540-2547.

[111]

F. van Rhee, S. Giralt, and B. Barlogie, “The Future of Autologous Stem Cell Transplantation in Myeloma,” Blood 124, no. 3 (2014): 328-333.

[112]

O. Landgren and R. G. Owen, “Better Therapy Requires Better Response Evaluation: Paving the Way for Minimal Residual Disease Testing for every myeloma Patient,” Cytometry Part B, Clinical Cytometry 90, no. 1 (2016): 14-20.

[113]

O. Landgren, S. Devlin, M. Boulad, and S. Mailankody, “Role of MRD Status in Relation to Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients: A Meta-analysis,” Bone Marrow Transplantation 51, no. 12 (2016): 1565-1568.

[114]

N. J. Gormley, D. M. Turley, J. S. Dickey, et al., “Regulatory Perspective on Minimal Residual Disease Flow Cytometry Testing in Multiple Myeloma,” Cytometry Part B, Clinical Cytometry 90, no. 1 (2016): 73-80.

[115]

A. M. Varghese, D. R. Howard, C. Pocock, et al., “Eradication of Minimal Residual Disease Improves Overall and Progression-free Survival in Patients With Chronic Lymphocytic Leukaemia, Evidence From NCRN CLL207: A Phase II Trial Assessing alemtuzumab Consolidation,” British Journal of Haematology 176, no. 4 (2017): 573-582.

[116]

N. Gökbuget, M. Kneba, T. Raff, et al., “Adult Patients With Acute Lymphoblastic Leukemia and Molecular Failure Display a Poor Prognosis and Are Candidates for Stem Cell Transplantation and Targeted Therapies,” Blood 120, no. 9 (2012): 1868-1876.

[117]

J. Holowiecki, M. Krawczyk-Kulis, S. Giebel, et al., “Status of Minimal Residual Disease After Induction Predicts Outcome in both Standard and High-risk Ph-negative Adult Acute Lymphoblastic Leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study,” British Journal of Haematology 142, no. 2 (2008): 227-237.

[118]

T. Raff, N. Gökbuget, S. Lüschen, et al., “Molecular Relapse in Adult Standard-risk ALL Patients Detected by Prospective MRD Monitoring During and After Maintenance Treatment: Data From the GMALL 06/99 and 07/03 Trials,” Blood 109, no. 3 (2007): 910-915.

[119]

O. Spinelli, B. Peruta, M. Tosi, et al., “Clearance of Minimal Residual Disease After Allogeneic Stem Cell Transplantation and the Prediction of the Clinical Outcome of Adult Patients With High-risk Acute Lymphoblastic Leukemia,” Haematologica 92, no. 5 (2007): 612-618.

[120]

S. Giebel, B. Stella-Holowiecka, M. Krawczyk-Kulis, et al., “Status of Minimal Residual Disease Determines Outcome of Autologous Hematopoietic SCT in Adult ALL,” Bone Marrow Transplantation 45, no. 6 (2010): 1095-1101.

[121]

N. Gökbuget, H. Dombret, M. Bonifacio, et al., “Blinatumomab for Minimal Residual Disease in Adults With B-cell Precursor Acute Lymphoblastic Leukemia [Published Correction Appears in Blood. 2019 Jun 13;133(24):2625,” Blood 131, no. 14 (2018): 1522-1531, https://doi.org/10.1182/blood.2019001109.

[122]

S. Choi, M. J. Henderson, E. Kwan, et al., “Relapse in Children With Acute Lymphoblastic Leukemia Involving Selection of a Preexisting Drug-resistant Subclone,” Blood 110, no. 2 (2007): 632-639.

[123]

A. Balduzzi, L. Di Maio, D. Silvestri, et al., “Minimal Residual Disease Before and After Transplantation for Childhood Acute Lymphoblastic Leukaemia: Is There any Room for Intervention?,” British Journal of Haematology 164, no. 3 (2014): 396-408.

[124]

T. Pincez, R. Santiago, H. Bittencourt, et al., “Intensive Monitoring of Minimal Residual Disease and Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in Children,” Bone Marrow Transplantation 56, no. 12 (2021): 2981-2989.

[125]

P. Bader, H. Kreyenberg, A. von Stackelberg, et al., “Monitoring of Minimal Residual Disease After Allogeneic Stem-cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial,” Journal of Clinical Oncology 33, no. 11 (2015): 1275-1284.

[126]

C. J. Knechtli, N. J. Goulden, J. P. Hancock, et al., “Minimal Residual Disease Status as a Predictor of Relapse After Allogeneic Bone Marrow Transplantation for Children With Acute Lymphoblastic Leukaemia,” British Journal of Haematology 102, no. 3 (1998): 860-871.

[127]

X. Li and X. Tong, “Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia,” CIA 18 (2023): 921-931.

[128]

Y. Jin, A. Y. Wang, X. B. Wang, H. Z. Yang, and X. Liu, “Clinical Study on Dynamic Detection of Minimal Residual Disease in Acute Myeloid Leukemia by Multiparameter Flow Cytometry,” Zhongguo Shi Yan Xue Ye Xue Za Zhi 30, no. 3 (2022): 737-743.

[129]

J. E. Rubnitz, H. Inaba, G. Dahl, et al., “Minimal Residual Disease-directed Therapy for Childhood Acute Myeloid Leukaemia: Results of the AML02 multicentre Trial,” The Lancet Oncology 11, no. 6 (2010): 543-552.

[130]

M. Terwijn, W. L. van Putten, A. Kelder, et al., “High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study,” Journal of Clinical Oncology 31, no. 31 (2013): 3889-3897.

[131]

F. Buccisano, R. Dillon, S. D. Freeman, and A. Venditti, “Role of Minimal (Measurable) Residual Disease Assessment in Older Patients With Acute Myeloid Leukemia,” Cancers (Basel) 10, no. 7 (2018): 215.

[132]

C. Wijnands, S. Noori, N. Donk, M. M. VanDuijn, and J. F. M. Jacobs, “Advances in Minimal Residual Disease Monitoring in Multiple Myeloma,” Critical Reviews in Clinical Laboratory Sciences 60, no. 7 (2023): 518-534.

[133]

I. Del Giudice, S. Raponi, I. Della Starza, et al., “Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?,” Frontiers in Oncology 9 (2019): 689.

[134]

N. J. Short, H. Kantarjian, F. Ravandi, et al., “High-sensitivity next-generation Sequencing MRD Assessment in ALL Identifies Patients at Very Low Risk of Relapse,” Blood Advances 6, no. 13 (2022): 4006-4014.

[135]

J. H. Park, I. Rivière, M. Gonen, et al., “Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia,” New England Journal of Medicine 378, no. 5 (2018): 449-459.

[136]

S. L. Maude, T. W. Laetsch, J. Buechner, et al., “Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia,” New England Journal of Medicine 378, no. 5 (2018): 439-448.

[137]

N. J. Short, E. Jabbour, W. Macaron, et al., “Ultrasensitive NGS MRD Assessment in Ph+ ALL: Prognostic Impact and Correlation With RT-PCR for BCR::ABL1,” American Journal of Hematology 98, no. 8 (2023): 1196-1203.

[138]

P. Bader, J. Hancock, H. Kreyenberg, et al., “Minimal Residual Disease (MRD) Status Prior to Allogeneic Stem Cell Transplantation Is a Powerful Predictor for Post-transplant Outcome in Children With ALL,” Leukemia 16, no. 9 (2002): 1668-1672.

[139]

A. Medina, N. Puig, J. Flores-Montero, et al., “Comparison of next-generation Sequencing (NGS) and next-generation Flow (NGF) for Minimal Residual Disease (MRD) Assessment in Multiple Myeloma,” Blood Cancer Journal 10, no. 10 (2020): 108.

[140]

N. Korde, M. Roschewski, A. Zingone, et al., “Treatment with Carfilzomib-Lenalidomide-Dexamethasone with Lenalidomide Extension in Patients with Smoldering or Newly Diagnosed Multiple Myeloma,” JAMA Oncology 1, no. 6 (2015): 746-754.

[141]

P. Martínez-Sánchez, L. Montejano, M. E. Sarasquete, et al., “Evaluation of Minimal Residual Disease in Multiple Myeloma Patients by Fluorescent-polymerase Chain Reaction: The Prognostic Impact of Achieving Molecular Response,” British Journal of Haematology 142, no. 5 (2008): 766-774.

[142]

R. Silvennoinen, T. Lundan, V. Kairisto, et al., “Comparative Analysis of Minimal Residual Disease Detection by Multiparameter Flow Cytometry and Enhanced ASO RQ-PCR in Multiple Myeloma,” Blood Cancer Journal 4, no. 10 (2014): e250.

[143]

K. Fukumoto, M. Fujisawa, Y. Suehara, et al., “Prognostic Impact of Immunophenotypic Complete Response in Patients With Multiple Myeloma Achieving Better Than Complete Response,” Leukemia & Lymphoma 57, no. 8 (2016): 1786-1792.

[144]

L. Rasche, D. Alapat, M. Kumar, et al., “Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma,” Leukemia 33, no. 7 (2019): 1713-1722.

[145]

R. Alonso, M. T. Cedena, A. Gómez-Grande, et al., “Imaging and Bone Marrow Assessments Improve Minimal Residual Disease Prediction in Multiple Myeloma,” American Journal of Hematology 94, no. 8 (2019): 853-861.

[146]

N. C. Munshi, H. Avet-Loiseau, K. C. Anderson, et al., “A Large Meta-analysis Establishes the Role of MRD Negativity in Long-term Survival Outcomes in Patients With Multiple Myeloma,” Blood Advances 4, no. 23 (2020): 5988-5999.

[147]

A. C. Winters, J. A. Gutman, E. Purev, et al., “Real-world Experience of Venetoclax With Azacitidine for Untreated Patients With Acute Myeloid Leukemia,” Blood Advances 3, no. 20 (2019): 2911-2919.

[148]

A. Maiti, C. D. DiNardo, S. A. Wang, et al., “Prognostic Value of Measurable Residual Disease After Venetoclax and Decitabine in Acute Myeloid Leukemia,” Blood Advances 5, no. 7 (2021): 1876-1883.

[149]

H. Takamatsu, R. K. Wee, Y. Zaimoku, et al., “A Comparison of Minimal Residual Disease Detection in Autografts Among ASO-qPCR, Droplet Digital PCR, and next-generation Sequencing in Patients With Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation,” British Journal of Haematology 183, no. 4 (2018): 664-668.

[150]

N. J. Short, S. Zhou, C. Fu, et al., “Association of Measurable Residual Disease with Survival Outcomes in Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis,” JAMA Oncology 6, no. 12 (2020): 1890-1899.

[151]

A. Hochhaus, R. A. Larson, F. Guilhot, et al., “Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia,” New England Journal of Medicine 376, no. 10 (2017): 917-927.

[152]

S. Böttcher, M. Ritgen, K. Fischer, et al., “Minimal Residual Disease Quantification Is an Independent Predictor of Progression-free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial,” Journal of Clinical Oncology 30, no. 9 (2012): 980-988.

[153]

M. Brüggemann, T. Raff, T. Flohr, et al., “Clinical Significance of Minimal Residual Disease Quantification in Adult Patients With Standard-risk Acute Lymphoblastic Leukemia,” Blood 107, no. 3 (2006): 1116-1123.

[154]

R. Bassan, O. Spinelli, E. Oldani, et al., “Improved Risk Classification for Risk-specific Therapy Based on the Molecular Study of Minimal Residual Disease (MRD) in Adult Acute Lymphoblastic Leukemia (ALL),” Blood 113, no. 18 (2009): 4153-4162.

[155]

S. Q. Li, M. Chen, X. Y. Huang, H. Wang, and Y. J. Chang, “Challenges Facing Minimal Residual Disease Testing for Acute Myeloid Leukemia and Promising Strategies to Overcome Them,” Expert Review of Hematology 16, no. 12 (2023): 981-990.

[156]

F. Tiso, T. N. Koorenhof-Scheele, E. Huys, et al., “Genetic Diversity Within Leukemia-associated Immunophenotype-defined Subclones in AML,” Annal of Hematology 101, no. 3 (2022): 571-579.

[157]

E. Coustan-Smith, G. Song, S. Shurtleff, et al., “Universal Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia,” JCI Insight 3, no. 9 (2018): e98561.

[158]

R. A. Brooimans, V. H. J. van der Velden, N. Boeckx, et al., “Immunophenotypic Measurable Residual Disease (MRD) in Acute Myeloid Leukemia: Is Multicentric MRD Assessment Feasible?,” Leukemia Research 76 (2019): 39-47.

[159]

B. Paiva, M. B. Vidriales, A. Sempere, et al., “Impact of Measurable Residual Disease by Decentralized Flow Cytometry: A PETHEMA Real-world Study in 1076 Patients With Acute Myeloid Leukemia,” Leukemia 35, no. 8 (2021): 2358-2370.

[160]

F. Guijarro, M. Garrote, N. Villamor, D. Colomer, J. Esteve, and M. López-Guerra, “Novel Tools for Diagnosis and Monitoring of AML,” Current Oncology 30, no. 6 (2023): 5201-5213.

[161]

J. S. Blachly, R. B. Walter, and C. S. Hourigan, “The Present and Future of Measurable Residual Disease Testing in Acute Myeloid Leukemia,” Haematologica 107, no. 12 (2022): 2810-2822.

[162]

S. Scott, R. Dillon, C. Thiede, et al., “Assessment of Acute Myeloid Leukemia Molecular Measurable Residual Disease Testing in an Interlaboratory Study,” Blood Advances 7, no. 14 (2023): 3686-3694.

[163]

F. Ravandi, J. Cloos, F. Buccisano, et al., “Measurable Residual Disease Monitoring in Patients With Acute Myeloid Leukemia Treated With Lower-intensity Therapy: Roadmap From an ELN-DAVID Expert Panel,” American Journal of Hematology 98, no. 12 (2023): 1847-1855.

[164]

N. Patkar, C. Kakirde, A. F. Shaikh, et al., “Clinical Impact of Panel-based Error-corrected next Generation Sequencing versus Flow Cytometry to Detect Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML),” Leukemia 35, no. 5 (2021): 1392-1404.

[165]

L. Gaksch, K. Kashofer, E. Heitzer, et al., “Residual Disease Detection Using Targeted Parallel Sequencing Predicts Relapse in Cytogenetically Normal Acute Myeloid Leukemia,” American Journal of Hematology 93, no. 1 (2018): 23-30.

[166]

M. H. Hansen, O. Cédile, T. S. Larsen, N. Abildgaard, and C. G. Nyvold, “Perspective: Sensitive Detection of Residual Lymphoproliferative Disease by NGS and Clonal Rearrangements-how Low Can You Go?,” Experimental Hematology 98 (2021): 14-24.

[167]

B. Wood, D. Wu, B. Crossley, et al., “Measurable Residual Disease Detection by High-throughput Sequencing Improves Risk Stratification for Pediatric B-ALL,” Blood 131, no. 12 (2018): 1350-1359.

[168]

E. C. Liang, S. E. Dekker, J. M. G. Sabile, et al., “Next-generation Sequencing-based MRD in Adults With ALL Undergoing Hematopoietic Cell Transplantation,” Blood Advances 7, no. 14 (2023): 3395-3402.

[169]

M. Kotrová, J. Koopmann, H. Trautmann, et al., “Prognostic Value of Low-level MRD in Adult Acute Lymphoblastic Leukemia Detected by Low- and High-throughput Methods,” Blood Advances 6, no. 10 (2022): 3006-3010.

[170]

S. Jaiswal and B. L. Ebert, “Clonal Hematopoiesis in human Aging and Disease,” Science 366, no. 6465 (2019): eaan4673.

[171]

D. P. Steensma, “Clinical Consequences of Clonal Hematopoiesis of Indeterminate Potential,” Blood Advances 2, no. 22 (2018): 3404-3410.

[172]

R. L. Bowman, L. Busque, and R. L. Levine, “Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies,” Cell Stem Cell 22, no. 2 (2018): 157-170.

[173]

L. P. Gondek, “CHIP: Is Clonal Hematopoiesis a Surrogate for Aging and Other Disease?,” Hematology Am Soc Hematol Educ Program 2021, no. 1 (2021): 384-389.

[174]

C. C. Coombs, A. Zehir, S. M. Devlin, et al., “Therapy-Related Clonal Hematopoiesis in Patients With Non-hematologic Cancers Is Common and Associated With Adverse Clinical Outcomes,” Cell Stem Cell 21, no. 3 (2017): 374-382. e4.

[175]

J. F. Soerensen, A. Aggerholm, G. B. Kerndrup, et al., “Clonal Hematopoiesis Predicts Development of Therapy-related Myeloid Neoplasms Post-autologous Stem Cell Transplantation,” Blood Advances 4, no. 5 (2020): 885-892.

[176]

T. Tanaka, K. Morita, S. Loghavi, et al., “Clonal Dynamics and Clinical Implications of Postremission Clonal Hematopoiesis in Acute Myeloid Leukemia,” Blood 138, no. 18 (2021): 1733-1739.

[177]

T. M. Robinson, R. L. Bowman, S. Persaud, et al., “Single-cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia,” Science Advances 9, no. 38 (2023): eadg0488.

[178]

S. Perakis and M. R. Speicher, “Emerging Concepts in Liquid Biopsies,” BMC Medicine [Electronic Resource] 15, no. 1 (2017): 75.

[179]

E. Heitzer, I. S. Haque, C. E. S. Roberts, and M. R. Speicher, “Current and Future Perspectives of Liquid Biopsies in Genomics-driven Oncology,” Nature Reviews Genetics 20, no. 2 (2019): 71-88.

[180]

R. Colmenares, N. Álvarez, S. Barrio, J. Martínez-López, and R. Ayala, “The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies,” Cancers (Basel) 14, no. 5 (2022): 1310.

[181]

B. L. Khoo, M. Shang, C. H. Ng, C. T. Lim, W. J. Chng, and J. Han, “Liquid Biopsy for Minimal Residual Disease Detection in Leukemia Using a Portable Blast Cell Biochip,” NPJ Precision Oncology 3 (2019): 30.

[182]

P. Ulz, E. Heitzer, J. B. Geigl, and M. R. Speicher, “Patient Monitoring Through Liquid Biopsies Using Circulating Tumor DNA,” International Journal of Cancer 141, no. 5 (2017): 887-896.

[183]

L. Maurillo, F. Buccisano, A. Spagnoli, et al., “Monitoring of Minimal Residual Disease in Adult Acute Myeloid Leukemia Using Peripheral Blood as an Alternative Source to Bone Marrow,” Haematologica 92, no. 5 (2007): 605-611.

[184]

Y. Jin, Z. J. Xu, D. Yu, et al., “Detection of NPM1 Mutations in Acute Myeloid Leukemia by Using Drop-Off Droplet Digital PCR and Its Clinical Application,” Clinical Laboratory 69, no. 11 (2023), https://doi.org/10.7754/Clin.Lab.2023.230537.

[185]

S. D. Freeman and C. S. Hourigan, “MRD Evaluation of AML in Clinical Practice: Are We There yet?,” Hematology-American Society of Hematology Education Program 2019, no. 1 (2019): 557-569.

[186]

T. Azenkot and B. A. Jonas, “Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia,” Cancers (Basel) 14, no. 15 (2022): 3634.

[187]

M. T. Voso, T. Ottone, S. Lavorgna, et al., “MRD in AML: The Role of New Techniques,” Frontiers in Oncology 9 (2019): 655.

[188]

T. Chatterjee, R. S. Mallhi, and S. Venkatesan, “Minimal Residual Disease Detection Using Flow Cytometry: Applications in Acute Leukemia,” Medical Journal Armed Forces India 72, no. 2 (2016): 152-156.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.